PE20150957A1 - Celulas para producir iduronato-2-sulfatasa recombinante - Google Patents

Celulas para producir iduronato-2-sulfatasa recombinante

Info

Publication number
PE20150957A1
PE20150957A1 PE2014002538A PE2014002538A PE20150957A1 PE 20150957 A1 PE20150957 A1 PE 20150957A1 PE 2014002538 A PE2014002538 A PE 2014002538A PE 2014002538 A PE2014002538 A PE 2014002538A PE 20150957 A1 PE20150957 A1 PE 20150957A1
Authority
PE
Peru
Prior art keywords
cells
sulfatase
produce recombinant
fge
recombinant iduronate
Prior art date
Application number
PE2014002538A
Other languages
English (en)
Spanish (es)
Inventor
Ferenc Boldog
Michael Heartlein
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of PE20150957A1 publication Critical patent/PE20150957A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0051Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/06Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y108/00Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/99Oxidoreductases acting on sulfur groups as donors (1.8) with other acceptors (1.8.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013Iduronate-2-sulfatase (3.1.6.13)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PE2014002538A 2012-06-29 2013-06-28 Celulas para producir iduronato-2-sulfatasa recombinante PE20150957A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261666719P 2012-06-29 2012-06-29

Publications (1)

Publication Number Publication Date
PE20150957A1 true PE20150957A1 (es) 2015-07-15

Family

ID=49778522

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014002538A PE20150957A1 (es) 2012-06-29 2013-06-28 Celulas para producir iduronato-2-sulfatasa recombinante

Country Status (27)

Country Link
US (3) US9150841B2 (OSRAM)
EP (1) EP2874649B1 (OSRAM)
JP (3) JP6067849B2 (OSRAM)
KR (1) KR101710487B1 (OSRAM)
CN (2) CN107267460A (OSRAM)
AU (3) AU2013282400B2 (OSRAM)
BR (1) BR112014032560B1 (OSRAM)
CA (1) CA2877521C (OSRAM)
CL (1) CL2014003568A1 (OSRAM)
CO (1) CO7240394A2 (OSRAM)
CR (1) CR20140586A (OSRAM)
DO (1) DOP2014000298A (OSRAM)
EA (2) EA202090805A1 (OSRAM)
ES (1) ES2718346T3 (OSRAM)
GT (1) GT201400302A (OSRAM)
HK (1) HK1209331A1 (OSRAM)
IL (3) IL236343A (OSRAM)
MX (2) MX336716B (OSRAM)
MY (2) MY189314A (OSRAM)
NZ (2) NZ703137A (OSRAM)
PE (1) PE20150957A1 (OSRAM)
PH (2) PH12016500011B1 (OSRAM)
SG (2) SG10201509397SA (OSRAM)
TR (1) TR201904435T4 (OSRAM)
UA (1) UA118955C2 (OSRAM)
WO (1) WO2014005019A2 (OSRAM)
ZA (1) ZA201409396B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10066000B2 (en) 2012-05-02 2018-09-04 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
US9550972B2 (en) 2014-09-29 2017-01-24 General Electric Company Devices, systems and methods for automated cell culturing
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
CA3001003A1 (en) 2015-10-05 2017-04-13 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
SG11202002730XA (en) 2017-10-02 2020-04-29 Denali Therapeutics Inc Fusion proteins comprising enzyme replacement therapy enzymes
JP7060235B2 (ja) * 2018-05-18 2022-04-26 国立大学法人広島大学 変異型イズロン酸-2-スルファターゼの機能回復薬剤のスクリーニング方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
CA2185324A1 (en) 1994-03-16 1995-09-21 Steven D. Rosen Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
WO2001018022A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins
EP2301947A3 (en) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
EP1171615B1 (en) 1999-04-26 2006-12-13 Genentech, Inc. Cell culture process for glycoproteins
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
AU2001238488A1 (en) 2000-02-17 2001-08-27 Incyte Genomics, Inc. Human kinases
JP2003527851A (ja) 2000-03-17 2003-09-24 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 7つのヒト卵巣および卵巣癌関連タンパク質
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
WO2002098455A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
JP4319979B2 (ja) 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド タンパク質の非アフィニティ精製
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
TWI312368B (en) 2002-12-23 2009-07-21 Bristol Myers Squibb Compan Mammalian cell culture processes for protein production
CN110496230A (zh) 2003-02-11 2019-11-26 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
ATE517917T1 (de) 2005-06-03 2011-08-15 Ares Trading Sa Herstellung eines rekombinanten il-18-bindenden proteins
CN101437839A (zh) 2006-03-20 2009-05-20 米德列斯公司 蛋白质纯化
HUE032074T2 (en) * 2008-01-18 2017-08-28 Biomarin Pharm Inc Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
JP5947214B2 (ja) * 2009-10-09 2016-07-06 ブルー キューブ アイピー エルエルシー 断熱栓流反応器及び該断熱栓流反応器を組み込んだプロセス
JP2013507131A (ja) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物
JPWO2011108451A1 (ja) 2010-03-01 2013-06-27 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
UA115649C2 (uk) 2010-06-25 2017-12-11 Шае Хюмен Дженетік Терапіс, Інк. Способи та композиції для доставки до цнс ідуронат-2-сульфатази
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제

Also Published As

Publication number Publication date
MX366155B (es) 2019-06-28
ZA201409396B (en) 2018-05-30
PH12016500011B1 (en) 2022-07-15
CN104540517A (zh) 2015-04-22
BR112014032560A2 (pt) 2018-03-06
IL254560A0 (en) 2017-11-30
JP6302499B2 (ja) 2018-03-28
KR101710487B1 (ko) 2017-02-27
ES2718346T3 (es) 2019-07-01
IL274266B (en) 2021-04-29
BR112014032560B1 (pt) 2022-04-26
PH12016500011A1 (en) 2019-08-14
US20180010108A1 (en) 2018-01-11
IL274266A (en) 2020-06-30
MX2015000189A (es) 2015-04-08
JP2016105737A (ja) 2016-06-16
TR201904435T4 (tr) 2019-05-21
CN107267460A (zh) 2017-10-20
AU2013282400B2 (en) 2016-02-04
MY189314A (en) 2022-02-04
NZ734670A (en) 2019-12-20
IL254560B (en) 2020-05-31
JP6067849B2 (ja) 2017-01-25
JP2018088933A (ja) 2018-06-14
HK1209651A1 (en) 2016-04-08
US20140004593A1 (en) 2014-01-02
US9719074B2 (en) 2017-08-01
MY157086A (en) 2016-04-19
SG11201408702VA (en) 2015-02-27
UA118955C2 (uk) 2019-04-10
EA201492183A1 (ru) 2015-06-30
IL236343A0 (en) 2015-02-26
AU2018200710A1 (en) 2018-02-22
EA035511B1 (ru) 2020-06-26
EP2874649B1 (en) 2019-01-02
EP2874649A4 (en) 2016-05-04
CL2014003568A1 (es) 2015-04-24
AU2013282400A1 (en) 2015-01-29
CA2877521C (en) 2021-06-01
PH12014502868B1 (en) 2015-02-23
EA202090805A1 (ru) 2020-11-30
CA2877521A1 (en) 2014-01-03
US9150841B2 (en) 2015-10-06
JP6755272B2 (ja) 2020-09-16
AU2016200460B2 (en) 2017-11-02
PH12014502868A1 (en) 2015-02-23
KR20150030242A (ko) 2015-03-19
NZ703137A (en) 2017-08-25
IL236343A (en) 2017-10-31
US20160053238A1 (en) 2016-02-25
HK1209331A1 (en) 2016-04-01
MX336716B (es) 2016-01-28
JP2015521848A (ja) 2015-08-03
DOP2014000298A (es) 2015-03-31
WO2014005019A3 (en) 2014-02-27
CO7240394A2 (es) 2015-04-17
SG10201509397SA (en) 2015-12-30
CR20140586A (es) 2015-04-06
EP2874649A2 (en) 2015-05-27
GT201400302A (es) 2019-05-22
WO2014005019A2 (en) 2014-01-03
AU2018200710B2 (en) 2019-11-14
AU2016200460A1 (en) 2016-02-18

Similar Documents

Publication Publication Date Title
PE20150957A1 (es) Celulas para producir iduronato-2-sulfatasa recombinante
IN2014DN11272A (OSRAM)
MX2016004564A (es) Cultivo celular metabolicamente optimizado.
NZ783252A (en) Compositions and methods for internalizing enzymes
EA201591817A1 (ru) Не содержащая сыворотки среда для культивирования клеток
GB2561496A (en) Devices and methods for simulating a function of a liver tissue
EA201590550A1 (ru) Композиции и способы получения гликопротеинов
MX363690B (es) Expansión de celulas madre adultas in vitro.
EA201490945A1 (ru) Набор, содержащий заменитель сыворотки и лабильные факторы
WO2019126641A3 (en) Modulation of frataxin expression
EA201170025A1 (ru) Способы повышения жизнеспособности и продукции культуры клеток
CA2830600C (en) Compositions and methods for enhancing the pluripotency of stem cells
EP4589002A3 (en) Use of monensin to regulate glycosylation of recombinant proteins
EA201992828A1 (ru) Способы культивирования клеток
MX2015010887A (es) Formulaciones y metodos para aumentar la produccion de proteinas recombinantes.
BR112015014328A2 (pt) Célula de mamífero capaz de propagar arterivírus, cultura celular, e, método para a propagação de um arterivírus em cultura celular
WO2015117033A3 (en) Methods of increasing protein production in mammalian cells
WO2020163467A3 (en) Uses of il-40 and methods for detecting il-40 activity
WO2020163469A3 (en) METHODS FOR DETECTING METEORIN-β ACTIVITY

Legal Events

Date Code Title Description
FC Refusal